This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. SABS, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Its Competitors SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Cytori Therapeutics (NASDAQ:CYTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Do analysts rate CYTX or SABS? SAB Biotherapeutics has a consensus price target of $13.25, indicating a potential upside of 374.91%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CYTX or SABS? Cytori Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CYTX or SABS? 2.6% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 0.7% of Cytori Therapeutics shares are owned by company insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CYTX or SABS more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Cytori Therapeutics' net margin of -242.60%. SAB Biotherapeutics' return on equity of -105.14% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% SAB Biotherapeutics N/A -105.14%-69.24% Does the media prefer CYTX or SABS? In the previous week, SAB Biotherapeutics had 1 more articles in the media than Cytori Therapeutics. MarketBeat recorded 1 mentions for SAB Biotherapeutics and 0 mentions for Cytori Therapeutics. SAB Biotherapeutics' average media sentiment score of 0.93 beat Cytori Therapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cytori Therapeutics Neutral SAB Biotherapeutics Positive Which has higher valuation & earnings, CYTX or SABS? Cytori Therapeutics has higher revenue and earnings than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M1.91-$12.63MN/AN/ASAB Biotherapeutics$1.32M19.64-$34.10M-$3.70-0.75 SummarySAB Biotherapeutics beats Cytori Therapeutics on 10 of the 14 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.03M$65.81M$5.57B$9.31BDividend YieldN/AN/A4.23%4.03%P/E RatioN/A5.0528.6119.73Price / Sales1.91193.85411.31174.27Price / CashN/A18.4136.0257.96Price / Book0.916.988.235.67Net Income-$12.63M-$25.02M$3.23B$257.79M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$0.32-5.7%N/A-81.0%$7.03M$3.67M0.0037High Trading VolumeSABSSAB Biotherapeutics3.1745 of 5 stars$2.58+31.6%$13.25+413.6%-12.4%$18.21M$1.32M-0.70140Gap UpHigh Trading VolumeCRISCuris2.5588 of 5 stars$1.85+6.3%$17.00+818.9%-73.6%$18.20M$10.91M-0.3060Positive NewsHigh Trading VolumeBOLTBolt Biotherapeutics3.0204 of 5 stars$6.04+2.9%$50.00+727.8%-61.0%$11.25M$7.69M-0.1890Positive NewsMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.3951 of 5 stars$297.00+1.4%$307.82+3.6%-11.4%$157.52B$33.42B27.1028,000Trending NewsAnalyst RevisionGILDGilead Sciences4.8915 of 5 stars$111.06-0.6%$111.38+0.3%+54.0%$139.05B$28.75B23.3817,600Trending NewsInsider TradeOptions VolumeAnalyst RevisionVRTXVertex Pharmaceuticals4.2882 of 5 stars$466.36+1.5%$511.62+9.7%-5.4%$117.98B$11.02B-118.976,100Trending NewsAnalyst ForecastAnalyst RevisionREGNRegeneron Pharmaceuticals4.8054 of 5 stars$547.75+1.8%$813.57+48.5%-49.4%$58.10B$14.20B13.9415,106ALNYAlnylam Pharmaceuticals4.139 of 5 stars$317.50-2.0%$341.91+7.7%+21.4%$42.26B$2.25B-151.912,230News CoveragePositive NewsAnalyst ForecastBIIBBiogen4.7844 of 5 stars$134.46+3.3%$188.48+40.2%-42.5%$19.07B$9.68B13.277,605Analyst Revision Related Companies and Tools Related Companies SABS Competitors CRIS Competitors BOLT Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTX Stock Alerts